Herceptin early-stage breast cancer user fee date extended
This article was originally published in The Pink Sheet Daily
Executive Summary
New deadline is November after Genentech provides FDA with additional analyses of previously submitted studies.
You may also be interested in...
Herceptin Approved For Early-Stage Adjuvant Breast Cancer
The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.
Herceptin Approved For Early-Stage Adjuvant Breast Cancer
The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.
Herceptin sBLA Submitted For Early-Stage Use
A supplemental BLA for an early adjuvant breast cancer indication for Herceptin will have a mid-August user fee date, if granted priority review